Navigation Links
Jennerex Announces First Patient Treated in Phase 2a Clinical Trial of JX-594 as a Neoadjuvant Therapy in Colorectal Cancer Patients Undergoing Surgery
Date:12/21/2011

SAN FRANCISCO, Dec. 21, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 2a clinical trial of JX-594 as a neoadjuvant therapy in patients who are undergoing surgery to treat colorectal cancer that has spread to the liver.

The study is being led by Rebecca Auer, M.D., surgical oncologist at The Ottawa Hospital, associate scientist at the Ottawa Hospital Research Institute and assistant professor of surgery at the University of Ottawa in Ottawa, Canada.  The clinical trial is being supported by funding from the Ontario Institute for Cancer Research­.

"This trial will allow us to evaluate the use of JX-594 in patients with surgically resectable disease, potentially expanding the role of this therapy in the treatment continuum," said David H. Kirn, M.D., president and chief medical officer of Jennerex.  "We continue to believe that JX-594 could play an integral role in the treatment of cancers and look forward to the results of this trial along with data from the larger Phase 2b study, called TRAVERSE, that is under way in patients with advanced hepatocellular carcinoma."

"In addition, this study will allow us to expand our analysis of the multi-mechanistic therapeutic activity of JX-594 through the examination of tumor specimens collected during surgery following JX-594 administration," said John C. Bell, Ph.D., senior scientist, cancer therapeutics, Ottawa Hospital Research Institute, and professor of medicine, University of Ottawa.  Dr. Bell is also the program leader of the Ontario Institute for Cancer Research's Immuno- and Bio-therapies Program.

This Phase 2a clinical trial will enroll approximately 20 patients with colorectal cancer metastases to the liver. Patients will receive a single
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
6. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
7. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
8. Jennerex Announces Presentations at Upcoming Conferences
9. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
10. Jennerex Appoints Lara Longpre to Chief Operating Officer
11. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  Encision Inc. (OTCQB:ECIA), a medical device company owning ... in minimally invasive surgery, today announced financial results for ... The Company posted quarterly net revenue of ... thousand, or $(0.02) per share. These results compare to ... of $311 thousand, or $(0.04) per share, in the ...
(Date:7/29/2014)... Health 2.0 announces Bernard Tyson , CEO of ... Topol , Patrick Soon-Shiong , and Samsung,s President ... Fall Conference this coming Sept. 21-24 in ... set to host the very first Wearable Tech Fashion Runway ... Tech & Wearables: Powering Healthy Lifestyles. The panel will ...
(Date:7/29/2014)... July 29, 2014   ... study investigating the efficacy and safety of MSB0010718C in patients ... a rare and aggressive skin cancer lacking effective treatments   ... cohort Phase I clinical trial for the treatment of solid ... EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, ...
Breaking Medicine Technology:Encision Reports First Quarter Fiscal Year 2015 Results 2Encision Reports First Quarter Fiscal Year 2015 Results 3Encision Reports First Quarter Fiscal Year 2015 Results 4Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:Satellite Dialysis Opens New Center in Merced, CA 2Satellite Dialysis Opens New Center in Merced, CA 3Satellite Dialysis Opens New Center in Merced, CA 4PDI Reports 2009 Fourth Quarter and Full Year Financial Results 2PDI Reports 2009 Fourth Quarter and Full Year Financial Results 3PDI Reports 2009 Fourth Quarter and Full Year Financial Results 4PDI Reports 2009 Fourth Quarter and Full Year Financial Results 5PDI Reports 2009 Fourth Quarter and Full Year Financial Results 6PDI Reports 2009 Fourth Quarter and Full Year Financial Results 7PDI Reports 2009 Fourth Quarter and Full Year Financial Results 8PDI Reports 2009 Fourth Quarter and Full Year Financial Results 9PDI Reports 2009 Fourth Quarter and Full Year Financial Results 10PDI Reports 2009 Fourth Quarter and Full Year Financial Results 11PDI Reports 2009 Fourth Quarter and Full Year Financial Results 12PDI Reports 2009 Fourth Quarter and Full Year Financial Results 13PDI Reports 2009 Fourth Quarter and Full Year Financial Results 14PDI Reports 2009 Fourth Quarter and Full Year Financial Results 15PDI Reports 2009 Fourth Quarter and Full Year Financial Results 16PDI Reports 2009 Fourth Quarter and Full Year Financial Results 17PDI Reports 2009 Fourth Quarter and Full Year Financial Results 18PDI Reports 2009 Fourth Quarter and Full Year Financial Results 19PDI Reports 2009 Fourth Quarter and Full Year Financial Results 20PDI Reports 2009 Fourth Quarter and Full Year Financial Results 21PDI Reports 2009 Fourth Quarter and Full Year Financial Results 22PDI Reports 2009 Fourth Quarter and Full Year Financial Results 23PDI Reports 2009 Fourth Quarter and Full Year Financial Results 24PDI Reports 2009 Fourth Quarter and Full Year Financial Results 25PDI Reports 2009 Fourth Quarter and Full Year Financial Results 26PDI Reports 2009 Fourth Quarter and Full Year Financial Results 27PDI Reports 2009 Fourth Quarter and Full Year Financial Results 28PDI Reports 2009 Fourth Quarter and Full Year Financial Results 29PDI Reports 2009 Fourth Quarter and Full Year Financial Results 30PDI Reports 2009 Fourth Quarter and Full Year Financial Results 31PDI Reports 2009 Fourth Quarter and Full Year Financial Results 32PDI Reports 2009 Fourth Quarter and Full Year Financial Results 33
(Date:7/29/2014)... suitable to find out which preferences patients have regarding ... economic evaluations, some (primarily methodological) issues still need to ... project by the German Institute for Quality and Efficiency ... (AHP), CA is the second method tested by the ... results to an overall value , In its ...
(Date:7/29/2014)... Imagine a future in which a new lung is grown ... material, or a day when an injection of replacement cells ... nerves or other tissues. , MULTIMEDIA ALERT: For audio and ... gift and regenerative medicine, visit the Mayo Clinic News ... longer science fiction, and a substantial gift from Jorge and ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Foot Levelers ... lecturer at the Florida Chiropractic Association (FCA) National Convention ... Effects on the Kinetic Chain Changes on Thursday, August ... talk is focusing on the positive impact functional foot ... such as low back pain, plantar fasciitis, and hammertoes. ...
(Date:7/29/2014)... 1WorldSync announces B. Braun Melsungen AG, ... utilize the Global Data Synchronization Network™ (GDSN®) standard ... product information with the U.S. Food and Drug ... global supply chain. Holger Clobes, Head of Global ... Braun serves customers in 61 countries, among others ...
(Date:7/29/2014)... July 29, 2014 Gummy smile surgeon ... and dark gums treatments that can enhance and perfect gummy ... balanced appearance that displays the teeth to their best advantage. ... tissue or have gums that are dark or discolored. Patients ... feel self-conscious about their smiles or experience a high level ...
Breaking Medicine News(10 mins):Health News:Determine patient preferences by means of conjoint analysis 2Health News:Determine patient preferences by means of conjoint analysis 3Health News:Determine patient preferences by means of conjoint analysis 4Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 2Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 3Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 4Health News:Foot Levelers CEO Kent Greenawalt Speaking at FCA Convention 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 3Health News:Gummy Smile Surgeon, Dr. Alex Farnoosh, Now Offers Procedures to Improve Gummy Smiles and Dark Gums 2
... Jan. 19 (HealthDay News) -- Many U.S. transplant surgeons ... to develop new safeguards that would protect and inform ... of transplant surgeons in the nation "overreacted" to a ... HIV after receiving organs from a single donor unknowingly ...
... 2011) Cancer scientists led by Dr. John Dick ... St Jude Children,s Research Hospital (Memphis) have found that ... them are organized in a more complex way than ... Nature (DOI:10.1038/nature09733), challenge the conventional scientific view ...
... By Charnicia Huggins HealthDay Reporter , ... tongue piercing as a form of self-expression, know that ... metal or plastic makes a difference when it comes ... collect more bacteria than plastic studs, potentially increasing the ...
... Physical Review X (PRX), an online, open access, primary ... As broad in scope as physics itself, PRX will publish ... will be of value to the global multidisciplinary readership. PRX ... an open access venue in accord with the strong reputation ...
... Ont., Jan. 19, 2011Health care systems around the world ... making decisions, causing inefficiencies and reduced quantity and quality ... field of "knowledge translation." "Failures to use research ... decision-maker groups," said Dr. Sharon Straus, a geriatrician and ...
... the world have been hot on the trail of a ... since the mutation,s discovery in 2008. The hunt is now ... Cancer Cell , researchers reveal how the mutation contributes to ... About 75 percent of people with low-grade brain tumors ...
Cached Medicine News:Health News:Cancer scientists discover genetic diversity in leukemic propagating cells 2Health News:Cancer scientists discover genetic diversity in leukemic propagating cells 3Health News:Metal Tongue Piercings Linked to Raised Infection Risks 2Health News:Metal Tongue Piercings Linked to Raised Infection Risks 3Health News:American Physical Society announces Physical Review X 2Health News:Health-care systems not using best evidence in decision-making 2Health News:Molecular battle in cancer cells offers clues for treatment 2
6.5mm diameter handpiece; 75mm handle with grooves for grip; Standard male luer taper fits most cannula hub and female luer taper....
Hook Shaped Tip , Curved to the Left; with 30 cm long silicone tubing with connector; overall length 40mm; stainless steel...
... forceps are designed for endomyocardial biopsies. ... a 3-pull ring handle, stainless steel cutting jaws, ... rotates to accommodate any position. ,A spring in ... jaws are opened by moving the double rings ...
The only solution for in-line digital measurement...
Medicine Products: